LARIMAR THERAPEUTICS, INC.: cashflow_financing
| Value | {"amount": -1808000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-03-31 |
| Status | superseded |
| Entity | LARIMAR THERAPEUTICS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T13:12:16.797926+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/ea6e4b24-8f5d-4f52-b474-1546bc666389
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001564590-20-022942 · Open the official SEC filing →Retrieved: 2026-08-19T13:12:16.797926+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001374690/cashflow-financing/2020-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/ea6e4b24-8f5d-4f52-b474-1546bc666389
History
- no predecessors — first report